Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab Q4W in Japanese Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT04738942Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jun 2021
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vedolizumab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Jun 2021; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT04738942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04738942.